2024
Biologics for Psoriasis
Wride A, Chen G, Spaulding S, Tkachenko E, Cohen J. Biologics for Psoriasis. Dermatologic Clinics 2024, 42: 339-355. PMID: 38796266, DOI: 10.1016/j.det.2024.02.001.Peer-Reviewed Original ResearchConceptsIL-23IL-17ALong-term risk-benefit profileTNF-aLong-term adverse eventsIL-23 inhibitorsTumor necrosis factor-alphaP19 subunit of IL-23Risk-benefit profileSubunit of IL-23TNF-a inhibitorsTreatment of psoriasisNecrosis factor-alphaHigher Psoriasis AreaRates of short-termIL-12/23Psoriasis AreaIL-17FAdverse eventsIL-12IL-17Factor-alphaP19 subunitInjectable biologicsP40 subunit
2022
Vaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide.
Fan R, Cohen JM. Vaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide. The Yale Journal Of Biology And Medicine 2022, 95: 249-255. PMID: 35782480, PMCID: PMC9235258.Peer-Reviewed Original ResearchConceptsAtopic dermatitis patientsBiologic therapyVaccination recommendationsDermatitis patientsTreatment of psoriasisNovel biologic therapiesIL-17IL-23Atopic dermatitisIL-12/23Vaccine administrationClinical dataHealthcare providersAvailable guidelinesPsoriasisTherapyUnique considerationsPatientsPractical guideVaccinationDermatitisTNFαInfectionDermatologistsAdministration